ZA200808961B - Combination comprising and iron chelator and an anti-neoplastic agent and use thereof - Google Patents

Combination comprising and iron chelator and an anti-neoplastic agent and use thereof

Info

Publication number
ZA200808961B
ZA200808961B ZA200808961A ZA200808961A ZA200808961B ZA 200808961 B ZA200808961 B ZA 200808961B ZA 200808961 A ZA200808961 A ZA 200808961A ZA 200808961 A ZA200808961 A ZA 200808961A ZA 200808961 B ZA200808961 B ZA 200808961B
Authority
ZA
South Africa
Prior art keywords
combination
neoplastic agent
iron chelator
chelator
iron
Prior art date
Application number
ZA200808961A
Other languages
English (en)
Inventor
Nick Hanspeter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200808961B publication Critical patent/ZA200808961B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200808961A 2006-05-09 2008-10-20 Combination comprising and iron chelator and an anti-neoplastic agent and use thereof ZA200808961B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74678806P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
ZA200808961B true ZA200808961B (en) 2009-08-26

Family

ID=38282831

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808961A ZA200808961B (en) 2006-05-09 2008-10-20 Combination comprising and iron chelator and an anti-neoplastic agent and use thereof

Country Status (17)

Country Link
US (2) US20090317489A1 (de)
EP (2) EP2026800A1 (de)
JP (1) JP2009536180A (de)
KR (1) KR20090007635A (de)
CN (1) CN101443002B (de)
AU (1) AU2007247112B2 (de)
BR (1) BRPI0711385A2 (de)
CA (1) CA2649792A1 (de)
IL (1) IL194819A0 (de)
MA (1) MA31130B1 (de)
MX (1) MX2008014292A (de)
NO (1) NO20084913L (de)
NZ (1) NZ572299A (de)
RU (1) RU2469721C2 (de)
TN (1) TNSN08447A1 (de)
WO (1) WO2007128820A1 (de)
ZA (1) ZA200808961B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512383A (ja) * 2008-02-19 2011-04-21 ノバルティス アーゲー 鉄キレート剤と免疫抑制剤の組合せ及びその使用
US20130011411A1 (en) * 2010-01-06 2013-01-10 Pestell Richard G Methods and compositions for the diagnosis, prognosis, and treatment of cancer
SG193494A1 (en) * 2011-03-21 2013-10-30 Vivolux Ab Treatment of solid tumours
AU2013318672B2 (en) 2012-09-21 2017-09-28 Vivolux Ab Means and method for treating solid tumours
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN110075120B (zh) * 2018-10-11 2022-03-11 广东众尔健生物科技有限公司 一种组合物及其在抗肿瘤药物中的应用
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7304882A (de) 1972-04-10 1973-10-12
CH605550A5 (de) 1972-06-08 1978-09-29 Research Corp
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (de) * 1985-11-25 1987-07-01 The Hospital For Sick Children Verwendung von Chelationsmitteln
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4939168A (en) 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9315802D0 (en) 1993-07-30 1993-09-15 Roussel Lab Ltd Chemical compounds
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제
US5618487A (en) 1995-02-21 1997-04-08 Hettinga; Siebolt Multi-clamp mold and method for clamping an injection mold assembly
EP1110953B1 (de) 1995-03-30 2009-10-28 Pfizer Products Inc. Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
CA2264908C (en) 1996-09-06 2006-04-25 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
BR0009507A (pt) 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2004006859A2 (en) * 2002-07-16 2004-01-22 Sonus Pharmaceuticals, Inc. Platinum compound
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1601367A2 (de) * 2003-02-06 2005-12-07 Bioresponse L.L.C. Kombinierte benutzung von kreuzblütler-indolen und chelatbildenden mitteln zur behandlung von durch den papillomavirus bedingten zuständen
GEP20094664B (en) * 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition

Also Published As

Publication number Publication date
CA2649792A1 (en) 2007-11-15
CN101443002A (zh) 2009-05-27
BRPI0711385A2 (pt) 2011-11-08
JP2009536180A (ja) 2009-10-08
MX2008014292A (es) 2008-11-18
WO2007128820A1 (en) 2007-11-15
AU2007247112A1 (en) 2007-11-15
CN101443002B (zh) 2012-03-21
NZ572299A (en) 2010-07-30
MA31130B1 (fr) 2010-02-01
RU2469721C2 (ru) 2012-12-20
NO20084913L (no) 2009-02-05
US20110159114A1 (en) 2011-06-30
RU2008148167A (ru) 2010-06-20
EP2272511A1 (de) 2011-01-12
AU2007247112B2 (en) 2010-08-26
EP2026800A1 (de) 2009-02-25
TNSN08447A1 (en) 2010-04-14
IL194819A0 (en) 2009-08-03
US20090317489A1 (en) 2009-12-24
KR20090007635A (ko) 2009-01-19

Similar Documents

Publication Publication Date Title
HUS2300039I1 (hu) PSMA-kötõ szerek és alkalmazásaik
HK1133381A1 (en) Antimicrobial agent and antimicrobial composition
EP1988084A4 (de) Metallkomplex und dessen anwendung
ZA200810200B (en) Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
HK1183435A1 (en) Frizzled-binding agents and uses thereof
EP1933884A4 (de) Abbildungswirkstoffe und verfahren zu ihrer verwendung
EP2042853A4 (de) Analysegerät und dessen verwendung
EP2048195A4 (de) Anorganisch-organische hybridzusammensetzung und verwendung davon
PL2018164T3 (pl) Zastosowanie preparatów złożonych obejmujących środki przeciwgrzybicze
EP2018163A4 (de) Abbildungsmittel und -verfahren
EP1865041A4 (de) Haftungsvermittler und haftungsvermittelnde harzemulsion
IL194819A0 (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
IL199904A0 (en) Compositions comprising a therapeutic agent and an alkoxy-polyethylene glycol and uses thereof
EP1837382A4 (de) Beschichtungswirkstoffzusammensetzung und ihre verwendung
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2058008A4 (de) Mittel gegen fettsucht und seine verwendung
EP2069371A4 (de) Organo-arsenoxid-verbindungen und deren verwendung
TWI372055B (en) The medical composition having the amount of dna damaging agent and the amount of tea polyphenols
GB2437457B (en) Game machine and self-running body for use therein
EP1759703A4 (de) Immunstimulierendes und interferonogenes mittel
HK1107046A1 (en) Game machine and self-running body for use therein
EP2000137A4 (de) Mittel zur triglyzeridsenkung und mittel gegen hyperinsulinismus
GB0625165D0 (en) Novel binding agents and uses thereof